Literature DB >> 27637718

The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial.

Matthew S Duprey1, Nada Al-Qadheeb2, Russel Roberts3, Yoanna Skrobik4, Greg Schumaker5, John W Devlin6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27637718      PMCID： PMC6988840          DOI： 10.1007/s00134-016-4512-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Torsades de Pointes associated with intravenous haloperidol in critically ill patients.

Authors:  N D Sharma; H S Rosman; I D Padhi; J E Tisdale
Journal:  Am J Cardiol       Date:  1998-01-15       Impact factor: 2.778

Review 2.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  J Am Coll Cardiol       Date:  2010-03-02       Impact factor: 24.094

3.  The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.

Authors:  J E Tisdale; S Rasty; I D Padhi; N D Sharma; H Rosman
Journal:  J Clin Pharmacol       Date:  2001-12       Impact factor: 3.126

4.  Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study.

Authors:  Nada S Al-Qadheeb; Yoanna Skrobik; Greg Schumaker; Manuel N Pacheco; Russel J Roberts; Robin R Ruthazer; John W Devlin
Journal:  Crit Care Med       Date:  2016-03       Impact factor: 7.598

5.  Antipsychotic use and diagnosis of delirium in the intensive care unit.

Authors:  Joshua T Swan; Kalliopi Fitousis; Jeffrey B Hall; S Rob Todd; Krista L Turner
Journal:  Crit Care       Date:  2012-05-16       Impact factor: 9.097
  5 in total
  5 in total

1.  Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval.

Authors:  Alexander Schmidt; Peter Fischer; Beate Wally; Joachim Scharfetter
Journal:  Neuropsychiatr       Date:  2017-08-08

2.  Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study.

Authors:  Marie O Collet; Jesús Caballero; Romain Sonneville; Fernando A Bozza; Peter Nydahl; Anna Schandl; Hilden Wøien; Giuseppe Citerio; Mark van den Boogaard; Johanna Hästbacka; Matthias Haenggi; Kirsten Colpaert; Louise Rose; Marija Barbateskovic; Theis Lange; Aksel Jensen; Martin B Krog; Ingrid Egerod; Helle L Nibro; Jørn Wetterslev; Anders Perner
Journal:  Intensive Care Med       Date:  2018-05-16       Impact factor: 17.440

3.  The use of a clinical decision support tool to assess the risk of QT drug-drug interactions in community pharmacies.

Authors:  Florine A Berger; Heleen van der Sijs; Teun van Gelder; Patricia M L A van den Bemt
Journal:  Ther Adv Drug Saf       Date:  2021-02-24

4.  Comparison of Antipsychotics for the Treatment of Patients With Delirium and QTc Interval Prolongation: A Clinical Decision Analysis.

Authors:  Ken Kurisu; Kazuhiro Yoshiuchi
Journal:  Front Psychiatry       Date:  2021-06-25       Impact factor: 4.157

5.  Effect of the antipsychotic drug haloperidol on arrhythmias during acute myocardial infarction in a porcine model.

Authors:  Stefan M Sattler; Anniek F Lubberding; Charlotte B Kristensen; Rasmus Møgelvang; Paul Blanche; Anders Fink-Jensen; Thomas Engstrøm; Stefan Kääb; Thomas Jespersen; Jacob Tfelt-Hansen
Journal:  Int J Cardiol Heart Vasc       Date:  2019-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.